POISED Study Supports Risk of Cessation of Oral Immunotherapy for Peanut Allergy; PACE Study Indicates Safer Peanut Allergy Treatment Approaches are Needed

New York, Nov. 07, 2019 (GLOBE NEWSWIRE) -- A major study recently published inThe Lancet, Sustained outcomes in oral immunotherapy for peanut allergy (POISED study), further validates the benefit of oral immunotherapy (OIT) for peanut allergy treatment and highlights the potential risks of allergy immunotherapy discontinuation.